Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback